Understanding urothelial carcinoma through cancer pathways
暂无分享,去创建一个
[1] W. Schulz,et al. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer , 2005, Molecular Cancer.
[2] Adel H Jebar,et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma , 2005, Oncogene.
[3] F. Schliess,et al. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. , 2003, Experimental cell research.
[4] R. Millikan,et al. Focus on bladder cancer. , 2004, Cancer cell.
[5] David M. Berman,et al. Tissue repair and stem cell renewal in carcinogenesis , 2004, Nature.
[6] W. Schulz,et al. Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. , 2000, Cancer research.
[7] R. Dahiya,et al. Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer. , 2002, The Journal of urology.
[8] T. Sun,et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation , 2001, Oncogene.
[9] T. Ørntoft,et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.
[10] H. von der Maase,et al. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. , 2002, Journal of the National Cancer Institute.
[11] M. Knowles,et al. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma , 2001, Oncogene.
[12] F. Rousseau,et al. Alteration of the PATCHED locus in superficial bladder cancer , 2003, Oncogene.
[13] Ekaterini Blaveri,et al. Bladder cancer outcome and subtype classification by gene expression. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] W. Schulz,et al. E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells , 2003, British Journal of Cancer.
[15] H. Moch,et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.
[16] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[17] Ishtiaq Rehman,et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Knowles,et al. Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype , 2005, Clinical Cancer Research.
[19] S. Groshen,et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Wallerand,et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.
[21] P. Hamilton,et al. Molecular pathology of non-invasive urothelial carcinomas (part I) , 2003, Virchows Archiv.
[22] W. Schulz,et al. Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. , 2000, Urology.
[23] I. Sesterhenn,et al. World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .
[24] Bai-Lin Wu,et al. High Intensity ras Signaling Induces Premature Senescence by Activating p38 Pathway in Primary Human Fibroblasts* , 2004, Journal of Biological Chemistry.
[25] W. Schulz,et al. Over‐expression and amplification of the c‐myc gene in human urothelial carcinoma , 1999, International journal of cancer.
[26] Christian Pilarsky,et al. Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder , 2005, Clinical Cancer Research.
[27] T. Ratliff. CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. , 2005, Journal of Urology.
[28] W. Schulz,et al. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. , 1998, British Journal of Cancer.
[29] M. Knowles,et al. What we could do now: molecular pathology of bladder cancer , 2001, Molecular pathology : MP.
[30] Rolf Ackermann,et al. Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder , 2004, Clinical Cancer Research.
[31] C. Pilarsky,et al. No evidence for involvement of beta-catenin and APC in urothelial carcinomas. , 2002, International journal of oncology.
[32] K. Shigeno,et al. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. , 2003, The Journal of urology.
[33] L. Kiemeney,et al. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer , 2004, Nature Medicine.
[34] M. Knowles,et al. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. , 2003, Cancer research.
[35] J. Cairns,et al. Allelotype of human bladder cancer. , 1994, Cancer research.
[36] Takashi Tsuruo,et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.
[37] T. H. van der Kwast,et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.
[38] Torben F. Ørntoft,et al. Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.
[39] W. Schulz,et al. Multiple mechanisms downregulate CDKN1C in human bladder cancer , 2005, International journal of cancer.
[40] Jennifer Southgate,et al. Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. , 2005, Experimental cell research.
[41] D. Ornstein. Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs , 2004 .
[42] P. Carroll,et al. Genetic alterations in primary bladder cancers and their metastases. , 1998, Cancer research.
[43] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.
[44] R. Löwer,et al. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas , 1999, British Journal of Cancer.
[45] R. Weinberg,et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene , 1982, Nature.
[46] Wen-Lin Kuo,et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. , 2003, Cancer research.
[47] Xue-Ru Wu. Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.
[48] E. Messing,et al. DBCCR1 mediates death in cultured bladder tumor cells , 2004, Oncogene.
[49] W. Schulz,et al. DNA Methylation and the Mechanisms of CDKN2A Inactivation in Transitional Cell Carcinoma of the Urinary Bladder , 2000, Laboratory Investigation.
[50] M. Wolter,et al. Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines , 2005, Journal of cellular physiology.
[51] R. Wooster,et al. Amplification and overexpression of E2F3 in human bladder cancer , 2004, Oncogene.
[52] T. Sun,et al. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. , 1999, Cancer research.
[53] G. Sauter,et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer , 2004, Oncogene.
[54] W. Schulz,et al. Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma , 2003, International journal of cancer.
[55] M. Knowles,et al. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer , 2001, Oncogene.
[56] I. Gromova,et al. Impact of proteomics on bladder cancer research. , 2004, Pharmacogenomics.
[57] N. Malats,et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.